Skip to main content
Fig. 1 | Alzheimer's Research & Therapy

Fig. 1

From: Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study

Fig. 1

Schematic drawing of QC inhibitor approach. pGlu-Aβ is posttranslationally formed by QC from N-terminally truncated Aβ versions carrying a glutamate at position N3 and N11. pGlu-Aβ seeds Aβ oligomers which are highly synaptotoxic and neurotoxic. Aβ amyloid beta, pGlu pyroglutamate, QC glutaminyl cyclase, sAPPβ soluble amyloid precursor protein beta

Back to article page
\